Y.S. Chi, chairman of Elsevier and director of RELX, doesn’t mince words when it comes to discussing the future of publishing. "No publisher will survive five years from today if they don't have data, ...
Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), results that can give the red-hot PD-(L)1xVEGF bispecific ...
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, announced the first reported median overall survival ...
Abstract: Outsourcing logistic regression classification services to the cloud is highly beneficial for streaming data. However, it raises critical privacy concerns for the input data and the training ...
Truth matters. Community matters. Your support makes both possible. LAist is one of the few places where news remains independent and free from political and corporate influence. Stand up for truth ...
Halfway through the first year of President Donald Trump’s second administration, an expansion in operations by Immigration and Customs Enforcement agents has led to a 123% increase from 2024 in ...
Forbes contributors publish independent expert analyses and insights. Randy Bean is a noted Senior Advisor, Author, Speaker, Founder, & CEO. How does a venerable American brand known for creating the ...
Abstract: In the context of evaluating machine learning algorithms for binary classification tasks, predicting passenger survival on the Titanic provides a practical benchmark. The research aims to ...
More than two years after the FDA held a public workshop on measuring overall survival (OS) in clinical cancer trials, the agency has released a draft guidance on the topic, recommending that OS be ...
Nestled deep in the eastern Himalayas, Bhutan is famed for its Gross National Happiness Index, pristine landscapes, and deep-rooted Buddhist traditions. But behind the prayer flags and mountaintop ...
The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback